<DOC>
	<DOCNO>NCT01011933</DOCNO>
	<brief_summary>This phase II trial study well selumetinib work treat patient recurrent persistent endometrial cancer come back persistent . Selumetinib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Selumetinib Treating Patients With Recurrent Persistent Endometrial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess activity AZD6244 ( selumetinib ) patient recurrent persistent endometrial cancer frequency patient survive progression-free least 6 month initiate therapy objective tumor response . II . To determine nature degree toxicity AZD6244 assess CTCAE v3.0 cohort patient . SECONDARY OBJECTIVE : I . To determine duration progression-free survival overall survival . EXPLORATORY OBJECTIVES : I . To explore association select biomarkers response AZD6244 ( progression-free survival status &gt; 6 month objective tumor response ) , measure clinical outcome ( progression-free survival overall survival ) disease status include histologic cell type . II . Mutations single nucleotide polymorphisms BRAF , KRAS2 , FGFR2 , PI3KCA , AKT1 , AKT2 , AKT3 PTEN DNA formalin-fixed paraffin-embedded ( FFPE ) tumor and/or normal blood cell . III . Immunohistochemical expression ERK , pERK , GSK3betta , pGSK3betta , PR-A , PR-B , pPR , ER-alpha , ER-beta , BRAF , KRAS , PTEN , EGFR , pEGFR , EGF , PELP1 MTA1s FFPE tumor . IV . To explore relationship among panel biomarkers evaluate cohort include mutation single nucleotide polymorphisms BRAF , KRAS2 , FGFR2 , PI3KCA , AKT1 , AKT2 , AKT3 PTEN well immunohistochemical expression ERK , pERK , GSK3betta , pGSK3betta , PR-A , PR-B , pPR , ER-alpha , ER-beta , BRAF , KRAS , PTEN , EGFR , pEGFR , EGF , PELP1 MTA1s . OUTLINE : This multicenter study . Patients receive selumetinib orally ( PO ) twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood archive tumor tissue sample collect biomarker study . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<criteria>Histologically confirmed* endometrial epithelial carcinoma , include follow cell type : Endometrioid adenocarcinoma Serous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Adenocarcinoma otherwise specify Mucinous adenocarcinoma Squamous cell carcinoma Transitional cell carcinoma Mesonephric carcinoma Recurrent persistent disease refractory curative therapy establish treatment Measurable disease , define ≥ 1 lesion measure ≥ 1 dimension ( long dimension record ) Each lesion must ≥ 20 mm measure conventional technique ( palpation , plain xray , CT scan , MRI ) OR ≥ 10 mm measure spiral CT scan Must ≥ 1 target lesion use assess response , define RECIST criterion Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence ≥ 90 day follow completion radiotherapy Must receive 1 prior chemotherapeutic regimen management endometrial carcinoma Chemotherapy administer radiosensitizer conjunction primary radiotherapy consider systemic chemotherapy regimen Not eligible high priority GOG protocol , one exist ( e.g. , active phase III GOG protocol patient population ) No prior concurrent CNS disease ( treat untreated ) physical examination , include primary brain tumor brain metastasis GOG performance status ( PS ) 02 ( patient receive 1 prior treatment regimen ) GOG PS 01 ( patient receive 2 prior treatment regimen ) ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN PT/INR ≤ 1.5 OR inrange INR ( 2 3 ) patient stable dose therapeutic warfarin PTT ≤ 1.5 time ULN Oxygen saturation ≥ 88 % room air QTc &lt; 450 msec EKG LVEF normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy No neuropathy ( sensory motor ) &gt; grade 1 No active infection require antibiotic Uncomplicated urinary tract infection allow No invasive malignancy within past 5 year except nonmelanoma skin cancer No serious , nonhealing wound , ulcer , bone fracture No history abdominal fistula gastrointestinal perforation No intraabdominal abscess within past 28 day No active bleed pathological condition would carry high risk bleeding ( e.g. , bleed disorder , coagulopathy , tumor involve major vessel ) No seizure control standard medical therapy No clinically significant cardiovascular disease include , limited , follow : Uncontrolled hypertension , define systolic BP &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg Myocardial infarction unstable angina within past 6 month NYHA class IIIV congestive heart failure Serious cardiac arrhythmia require medication , include atrial fibrillation require ratecontrolling medication Peripheral vascular disease ≥ grade 2 Cerebrovascular accident ( i.e. , CVA , stroke ) , transient ischemic attack , subarachnoidal hemorrhage within past 6 month No evidence serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) EKG Concurrent low molecular weight heparin treatment venous thromboembolic disease allow provide patient consider clinically stable regimen Recovered prior surgery , radiotherapy , chemotherapy At least 1 week since prior hormonal therapy direct malignant tumor At least 3 week since prior radiotherapy chemotherapy ( 6 week nitrosoureas mitomycin C ) At least 3 week since prior therapy direct malignant tumor , include immunologic agent One prior cytotoxic regimen management recurrent persistent endometrial disease allow No prior noncytotoxic chemotherapy management endometrial cancer , except hormonal therapy No prior anticancer therapy contraindicates study therapy No prior MEK inhibitor AZD6244 specific MEK/ERK/MAPK pathway target therapy No prior chemotherapy abdominal pelvic tumor treatment endometrial cancer within past 5 year Prior adjuvant chemotherapy localize breast cancer allow provide complete &gt; 3 year ago AND patient remain free recurrent metastatic disease No prior radiotherapy portion abdominal cavity pelvis treatment endometrial cancer within past 5 year Prior radiotherapy localize cancer breast , head neck , skin allow provide complete &gt; 3 year ago AND patient remain free recurrent metastatic disease No concurrent medication may prolong QTc interval No concurrent investigational therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>